Actonel provides vertebral fracture risk reduction.

Publication: Pharma Business Week

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 NewsRX

2004 NOV 15 - (NewsRx.com & NewsRx.net) -- Actonel (risedronate sodium tablets) reduces the risk of vertebral fracture up to 62% at 1 year in women with postmenopausal osteoporosis who are at risk for upper gastrointestinal (GI) side effects, according to new analyses presented at the American College of Rheumatology (ACR) annual meeting.

"These data are further evidence that Actonel provides fracture risk reduction across a broad range of postmenopausal women with osteoporosis, even those prone to experiencing GI side effects," said Karen Hansen, assistant professor of medicine, Rheumatology Division, University of Wisconsin Department of Medicine and chief of rheumatology, VA Hospital, Madison, Wisconsin.

"Importantly, the study also shows that women who take medications which reduce stomach acid receive the same benefit as the overall Actonel-treated population," Hansen said.

Actonel is the only osteoporosis therapy proven to reduce...

Read the full article for free courtesy of your local library.